Currently, the precise effect of IFNs on anti-tumor immunity in the presence of PD-L1 inhibitors remains enigmatic because they can, somewhat paradoxically, both protect and weaken immune defenses (often simultaneously) (Benci et al, 2019; Benci et al, 2016). This evidence concerns the gene CD274 and neoplasm.